Publicaciones en las que colabora con Jaime Feliu Batlle (15)

2023

  1. Prognostic evaluation in patients with advanced cancer in the last months of life: ESMO Clinical Practice Guideline ☆

    ESMO Open, Vol. 8, Núm. 2

  2. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402

    Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1497-1505

2019

  1. Clinical impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer treated with first-line chemotherapy plus anti–epidermal growth factor receptor therapy

    JCO Precision Oncology, Vol. 3

2018

  1. Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients

    Neoplasia (United States), Vol. 20, Núm. 7, pp. 678-686

2017

  1. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial

    Tumor Biology, Vol. 39, Núm. 6

  2. Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

    British Journal of Cancer, Vol. 117, Núm. 12, pp. 1777-1786

2015

  1. Clinical guideline SEOM: hepatocellular carcinoma

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 988-995

  2. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer

    PLoS ONE, Vol. 10, Núm. 1

2014

  1. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study

    British Journal of Cancer, Vol. 111, Núm. 2, pp. 241-248

  2. Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: The GEMCAD 0801 phase II multicenter trial

    Oncologist, Vol. 19, Núm. 10, pp. 1042-1043

2011

  1. Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain

    Clinical and Translational Oncology, Vol. 13, Núm. 11, pp. 798-804

2010

  1. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

    British Journal of Cancer, Vol. 102, Núm. 10, pp. 1468-1473

2006

  1. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer

    British Journal of Cancer, Vol. 94, Núm. 7, pp. 969-975

2005

  1. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer

    British Journal of Cancer, Vol. 93, Núm. 11, pp. 1230-1235

2004

  1. Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: A phase II study

    British Journal of Cancer, Vol. 90, Núm. 8, pp. 1502-1507